相关临床试验
0
0 进行中
药物批准
5
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Private equity firm Warburg Pincus is nearing a deal to acquire specialty pharmacy PANTHERx Rare for more than $7 billion, including debt, according to the Wall Street Journal. - Warburg Pincus is partnering with the Abu Dhabi Investment Authority on the acquisition, though the deal is not yet finalized and timing could still slip. - Pittsburgh-based PANTHERx Rare specializes in providing medicines and patient support services for rare and orphan diseases, a critical niche in the pharmaceutical supply chain. - The acquisition reflects growing private equity interest in specialty pharmacy assets amid a backlog of portfolio companies seeking exits.
- Simtra BioPharma Solutions has completed construction of a new 1,800 square meter production facility at its Halle, Germany campus, expanding total production area to nearly 12,000 square meters. - The expansion creates 150 new jobs and adds four freeze dryers, bringing the site's total to 15 units, while introducing prefilled syringe technology for the first time at the German facility. - The facility enhances Simtra's capacity for sterile fill/finish services including vial filling for liquid and lyophilized products, supporting development of targeted cancer treatments and other critical injectable therapeutics. - This expansion follows Simtra's strategic investments including a $250 million facility expansion in the US and a partnership with Merck KGaA to support antibody-drug conjugate manufacturing.
- Simtra BioPharma Solutions and MilliporeSigma have established a five-year strategic alliance to create a turnkey offering for antibody-drug conjugate manufacturing and bioconjugation services. - The partnership aims to address the complexity of ADC manufacturing by creating a seamless value chain where MilliporeSigma handles drug substance conjugation and Simtra manages fill-finish operations. - With over 200 ADCs currently in clinical trials and the ADC manufacturing market expected to grow from $1.79 billion to $7 billion by 2035, the alliance targets significant industry demand. - The collaboration is designed to reduce development timelines and complexity for biopharmaceutical companies, allowing them to focus on drug discovery while ensuring quality standards.
- Simtra BioPharma Solutions announced a $14 million investment to expand clinical-scale conjugation and purification capabilities for antibody-drug conjugates at its Germany facility. - The new clinical suite will be operational by late 2025 and will offer conjugation mixing, single-use tangential flow filtration, and diafiltration capabilities. - This expansion positions Simtra as an end-to-end service provider for ADC development, from early development through commercial production. - The investment strengthens Simtra's leadership in the growing ADC manufacturing sector and aims to accelerate time to market for customers.
